Milan Panić

 (Serbian Cyrillic: Милан Панић, pronounced [mǐlan pǎːnit͡ɕ]; 20 December 1929 – 24 September 2026) 

https://en.wikipedia.org/wiki/Milan_Pani%C4%87

...  In 2002, ICN settled an SEC civil lawsuit related to misleading statements issued regarding their products.^[48][49] Panić decided to retire as CEO and Chairman of ICN in June 2002 after opposing shareholders took control of ICN's Board of Directors.^[50] Over the course of his career as Chairman, CEO, and President, Panić led ICN to annual sales in 90 countries exceeding $672 million (USD), with over 600 drugs in its portfolio by his final year in 2001.^[22][51][52]

Panić maintained other business entities and investments both in the U.S. and internationally. In 2003, after Panić's departure, ICN Pharmaceuticals changed its name to Valeant Pharmaceuticals International, Inc.^[53]

After retiring from ICN, Panić bought a bioassay subsidiary of ICN Biomedicals and changed its name to MP Biomedicals.^[54] MP specializes in research and development of life science and diagnostic products.^[55] MP's global headquarters is located in Santa Ana, California, with its U.S. headquarters and central distribution center located in Solon, Ohio. The company maintains global operations in North America, South America, Asia, Australia, and Europe. On 14 June 2010, Panić and MP acquired ICPBio International LTD., a New Zealand-based protein biologics manufacturing company.^[56] On 11 December 2014, the FDA approved MP Diagnostics HTLV Blot 2.4, the first FDA-licensed supplemental test for Human T-cell Lymphotropic Virus-I/II (HTLV-I/II).^[57] In October 2015, Panić announced the sale of MP Biomedicals to China-based Valiant Fine Chemicals Co. Ltd., a developer of chemical products.^[55]